Back to search results

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed Refractory Multiple Myeloma (RRMM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Andrew J. Yee, MD) · ayee1@mgh.harvard.edu · 617-724-4000
    Contact: Principal Investigator (Andrew J. Yee, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Jessica Leigel, MD) · jliegel@bidmc.harvard.edu · 617-667-9920
    Contact: Principal Investigator (Jessica Liegel, MD)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Shonali Midha, MD) · shonali_midha@dfci.harvard.edu · 617-632-3823
    Contact: Principal Investigator (Shonali Midha, MD)
Study leads

  • Andrew J. Yee, MD

    Principal Investigator

    Massachusetts General Hospital

View source on ClinicalTrials.gov(opens in a new tab)